ROS1阳性非小细胞肺癌靶向治疗的研究进展

doi:10.3760/cma.j.issn.1673-422X.2019.12.008

摘要/Abstract

摘要： ROS1融合基因作为非小细胞肺癌（NSCLC）分子靶向治疗又一新的潜力靶点，近年来，越来越多的学者将焦点转移到ROS1融合基因上。体外实验和临床研究结果均显示，间变性淋巴瘤激酶(ALK)抑制剂对ROS1阳性NSCLC患者具有明显的抗肿瘤活性，但仍不可避免出现耐药。目前ROS1阳性NSCLC尚无标准化诊疗方案。因此，针对ROS1的ALK抑制剂的进一步研究至关重要，可为NSCLC患者靶向治疗和研究提供新的治疗思路。

关键词: 癌, 非小细胞肺, 分子靶向治疗, ROS1融合基因

Abstract: ROS1 fusion gene is a new potential target for molecular targeted therapy of non-small cell lung cancer (NSCLC). In recent years, more and more scholars focus on ROS1 fusion gene. The results of in vitro experiments and clinical research both show that anaplastic lymphoma kinase (ALK) inhibitors have potent anti-tumor activity in ROS1-positive NSCLC patients, but drug resistance is still inevitable. At present, there is no standardized diagnosis and treatment path for ROS1-positive NSCLC. Therefore, further study on the ALK inhibitors of ROS1 is very important, which can provide a new therapeutic idea for targeted treatment and research of NSCLC patients.

Key words: Carcinoma, non-small-cell lung, Molecular targeted therapy, ROS1 fusion gene

金瑶, 翁一鸣, 胥泽玺, 彭敏. ROS1阳性非小细胞肺癌靶向治疗的研究进展[J]. 国际肿瘤学杂志, 2019, 46(12): 745-749.

Jin Yao, Weng Yiming, Xu Zexi, Peng Min. Research progress on targeted treatment in ROS1-positive non-small cell lung cancer[J]. Journal of International Oncology, 2019, 46(12): 745-749.

参考文献［34］

［1］	Park S, Ahn BC, Lim SW, et al. Characteristics and outcome of ROS1-positive non-small cell lung cancer patients in routine clinical practice［J］. J Thorac Oncol, 2018, 13(9): 1373-1382. DOI: 10.1016/j.jtho.2018.05.026.
［2］	Kim HR, Lim SM, Kim HJ, et al. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma［J］. Ann Oncol, 2013, 24(9): 2364-2370. DOI: 10.1093/annonc/mdt220.
［3］	Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer［J］. N Engl J Med, 2014, 371(21): 1963-1971. DOI: 10.1056/NEJMoa1406766.
［4］	Liu C, Yu H, Chang J, et al. Crizotinib in Chinese patients with ROS1-rearranged advanced non-small-cell lung cancer in routine clinical practice［J］. Target Oncol, 2019, 14(3): 315-323. DOI: 10.1007/s11523-019-00636-6.
［5］	Katsurada N, Tachihara M, Jimbo N, et al. Successful treatment of ROS1-rearranged lung cancer complicated by hypertrophic pulmonary osteoarthropathy with crizotinib therapy［J］. Intern Med, 2019, 58(10): 1467-1471. DOI: 10.2169/internalmedicine.1982-18.
［6］	Morris TA, Khoo C, Solomon BC. Targeting ROS1 rearrangements in non-small cell lung cancer: crizotinib and newer generation tyrosine kinase inhibitors［J］. Drugs, 2019, 79(12): 1277-1286. DOI: 10.1007/s40265-019-01164-3.
［7］	Créquit P, Ruppert AM, Rozensztajn N, et al. EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients［J］. Lung Cancer, 2016, 96: 74-77. DOI: 10.1016/j.lungcan.2015.11.021.
［8］	Kerner GS, Koole MJ, Bongaerts AH, et al. Total body metabolic tumor response in ALK positive non-small cell lung cancer patients treated with ALK inhibition［J］. PLoS One, 2016, 11(5): e0149955. DOI: 10.1371/journal.pone.0149955.
［9］	Juan O, Popat S. Crizotinib for ROS1 patients: one small step in bio-marker testing, one giant leap for advanced NSCLC patients［J］. Lung Cancer, 2017, 104: 131-133. DOI: 10.1016/j.lungcan.2016.11.007.
［10］	Mazières J, Zalcman G, Crinò L, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort［J］. J Clin Oncol, 2015, 33(9): 992-999. DOI: 10.1200/JCO.2014.58.3302.
［11］	Shen L, Lu S. Crizotinib versus pemetrexed-based chemotherapy in patients with advanced ROS1-rearranged non-small cell lung cancer［J］. J Clin Oncol, 2019, 37(15_suppl): 9101. DOI: 10.1200/JCO.2019.37.15_suppl.9101.
［12］	Sebastian Yves Friedrich Michels, Franklin J, Massuti B, et al. Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): a European phase Ⅱ clinical trial-updated report on progression-free and overall survival［J］. J Clin Oncol, 2019, 37(15_suppl): 9066. DOI: 10.1200/JCO.2019.37.15_suppl.9066.
［13］	Gainor JF, Tseng D, Yoda S, et al. Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small-cell lung cancer［J］. JCO Precis Oncol, 2017, 2017. DOI: 10.1200/PO.17.00063.
［14］	Roys A, Chang X, Liu Y, et al. Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer［J］. Cancer Chemother Pharmacol, 2019, 84(4): 679-688. DOI: 10.1007/s00280-019-03902-6.
［15］	Muller IB, De Langen AJ, Honeywell RJ, et al. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib［J］. Expert Rev Anticancer Ther, 2016, 16(2): 147-157. DOI: 10.1586/14737140.2016.1131612.
［16］	Gainor JF, Shaw AT. Fast, food and ceritinib in ALK-positive NSCLC［J］. J Thorac Oncol, 2017, 12(9): 1341-1343. DOI: 10.1016/j.jtho.2017.07.012.
［17］	Lim SM, Kim HR, Lee JS, et al. Open-label, multicenter, phase Ⅱ study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement［J］. J Clin Oncol, 2017, 35(23): 2613-2618. DOI: 10.1200/JCO.2016.71.3701.
［18］	Drilon A, Barlesi F, De Braud F, et al. Entrectinib in locally advanced or metastatic ROS1 fusion positive non-small cell lung cancer (NSCLC): integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2［J］. Ann Oncol, 2019, 30(Supplement_2). DOI: 10.1093/annonc/mdz063.007.
［19］	Ardini E, Menichincheri M, Banfi P, et al. Entrectinib, a Pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications［J］. Mol Cancer Ther, 2016, 15(4): 628-639. DOI: 10.1158/1535-7163.MCT-15-0758.
［20］	Doebele RC, Petez L, Trinh H, et al. Time-to-treatment discontinuation (TTD) and real-world progression-free survival (rwPFS) as endpoints for comparative efficacy analysis between entrectinib trial and crizotinib real-world ROS1 fusion-positive (ROS1+) NSCLC patients［J］. J Clin Oncol, 2019, 37(15_suppl): 9070. DOI: 10.1200/JCO.2019.37.15_suppl.9070.
［21］	Ahn MJ, Cho BC, Siena S, et al. Entrectinib in patients with locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC)［J］. J Thorac Oncol, 2017, 12(11): S1783. DOI: 10.1016/j.jtho.2017.09.411.
［22］	Davare MA, Vellore NA, Wagner JP, et al. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors［J］. Proc Natl Acad Sci U S A, 2015, 112(39): E5381-E5390. DOI: 10.1073/pnas.1515281112.
［23］	Gettinger SN, Bazhenova LA, Langer CJ, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial［J］. Lancet Oncol, 2016, 17(12): 1683-1696. DOI: 10.1016/S1470-2045(16)30392-8.
［24］	Chong CR, Bahcall M, Capelletti M, et al. Identification of existing drugs that effectively target NTRK1 and ROS1 rearrangements in lung cancer［J］. Clin Cancer Res, 2017, 23(1): 204-213. DOI: 10.1158/1078-0432.CCR-15-1601.
［25］	Drilon A, Somwar R, Wagner JP, et al. A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer［J］. Clin Cancer Res, 2016, 22(10): 2351-2358. DOI: 10.1158/1078-0432.CCR-15-2013.
［26］	Katayama R, Kobayashi Y, Friboulet L, et al. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer［J］. Clin Cancer Res, 2015, 21(1): 166-174. DOI: 10.1158/1078-0432.CCR-14-1385.
［27］	Hellerstedt BA, Vogelzang NJ, Kluger HM, et al. Results of a phase Ⅱ placebo-controlled randomized discontinuation trial of cabozantinib in patients with non-small-cell lung carcinoma［J］. Clin Lung Cancer, 2019, 20(2): 74-81, e1. DOI: 10.1016/j.cllc.2018.10.006.
［28］	Zou HY, Friboulet L, Kodack DP, et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models［J］. Cancer Cell, 2015, 28 (1): 70-81. DOI: 10.1016/j.ccell.2015.05.010.
［29］	Solomon B, Shaw A, Ou S, et al. Phase 2 study of lorlatinib in patients with advanced ALK+/ROS1+non-small-cell lung cancer［J］. J Thorac Oncol, 2017, 12(11): S1756. DOI: 10.1016/j.jtho.2017.09.351.
［30］	Ou S, Shaw A, Rielyet G, et al. Clinical activity of lorlatinib in patients with ROS1+ advanced non-small cell lung cancer: phase 2 study cohort EXP-6［J］. J Thorac Oncol, 2018, 13(10): S322-S323. DOI: 10.1016/j.jtho.2018.08.241.
［31］	Cui JJ, Zhai D, Deng W, et al. TPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants［J］. Eur J Cancer, 2016, 69(Supplement 1): S32. DOI: 10.1016/S0959-8049(16)32675-2.
［32］	Cui JJ, Zhai D, Deng W, et al. Abstract B185: TPX-0005, a supreme ROS1 inhibitor, overcomes crizotinib-resistant ROS1 mutations including solvent front mutation G2032R and gatekeeper mutation L2026M［J］. Mol Cancer Ther, 2018, 17(1_suppl): B185. DOI: 10.1158/1535-7163.TARG-17-B185.
［33］	Drilon AE, Kim DW, Lee J, et al. A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1)［J］. J Clin Oncol, 2018, 36(15_suppl): 2513. DOI: 10.1200/JCO.2018.36.15_suppl.2513.
［34］	Drilon A, Ou SI, Cho BC, et al. Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent- front mutations［J］. Cancer Discov, 2018, 8(10): 1227-1236. DOI: 10.1158/2159-8290.CD-18-0484.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[4]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[5]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[6]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[7]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[8]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[9]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[10]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[11]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[12]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[13]	胡婷婷, 王越华. 电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[14]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[15]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.